GlaxoSmithKline
The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk, treatment and progression. This proposal seeks to collect additional subject-level data from SLS patients via their electronic medical records (encompassing past and future data for up to 10 years from the date of consent) and via a one-off patient questionnaire administered at the time of consent.
Asthma
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 3500 participants |
Official Title : | The Extended Salford Lung Study ("Ex-SLS") Data Access Project |
Actual Study Start Date : | 2018-04-15 |
Estimated Primary Completion Date : | 2028-04-30 |
Estimated Study Completion Date : | 2028-04-30 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
GSK Investigational Site
Manchester, United Kingdom, 4 am